Dengue Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

DF MCID: DNG003 MIFTS: 69	Dengue Disease (DF) Categories: Blood diseases, Genetic diseases, Infectious diseases, Liver diseases, Muscle diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease ¹¹ ¹⁴ ¹⁶

Dengue Fever ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ² ¹⁴ ⁷¹

Dengue ⁵³ ⁴¹ ⁴³ ³³

Df ¹⁹ ⁵⁸ ²

Dengue Virus Infection ¹⁹ ⁵⁸

Dengue Shock Syndrome ¹⁹ ⁷¹

Dengue Haemorrhagic Fever Without Warning Signs ³³

Dengue Haemorrhagic Fever with Warning Signs ³³

Dengue Fever Without Warning Signs ³³

Dengue Haemorrhagic Fever Grade 1 ³³

Southeast Asia Haemorrhagic Fever ³³

Dengue Haemorrhagic Fever Grade 2 ³³

Dhf -[dengue Haemorrhagic Fever] ³³

Dengue Fever with Warning Signs ³³

Philippine Haemorrhagic Fever ³³

Philippine Hemorrhagic Fever ¹⁹

Singapore Haemorrhagic Fever ³³

Singapore Hemorrhagic Fever ¹⁹

Thailand Haemorrhagic Fever ³³

Bangkok Haemorrhagic Fever ³³

Dengue Hemorrhagic Fever ¹⁹

Thai Hemorrhagic Fever ¹⁹

Hemorrhagic Dengue ¹⁹

Classical Dengue ¹¹

Breakbone Fever ¹¹

Classic Dengue ¹¹

Severe Dengue ⁷¹

Characteristics:

Prevelance:

Dengue Fever: >1/1000 (Worldwide) 1-9/1000000 (Europe, Belgium, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Portugal, Slovenia, Spain, United Kingdom) 1-9/100000 (Europe, Austria, Sweden, Norway) <1/1000000 (Croatia, Luxembourg, Slovakia, Greece) ⁵⁸

Age Of Onset:

Dengue Fever: All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Genetic diseases
Anatomical: Skin diseases Muscle diseases Blood diseases Liver diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Arthropod-borne viral fevers and viral haemorrhagic fevers

Dengue fever [classical dengue]

ICD11: ³³

Certain infectious or parasitic diseases

Dengue

Dengue fever, unspecified

Dengue with warning signs

Dengue without warning signs

Orphanet: ⁵⁸

Rare infectious diseases

Sources

Summaries for Dengue Disease

MedlinePlus: ⁴¹ Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found: Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows

MalaCards based summary: Dengue Disease, also known as dengue fever, is related to dengue shock syndrome and dengue hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Dengue Disease is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and endothelial, and related phenotypes are fever and headache

Disease Ontology: ¹¹ A viral infectious disease that results in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

CDC: ² Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world's population, about 3 billion people, live in areas with a risk of dengue. Dengue is often a leading cause of illness in areas with risk.

GARD: ¹⁹ Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).

Orphanet: ⁵⁸ Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).

Wikipedia: ⁷⁵ Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Sources

Related Diseases for Dengue Disease

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 920)

#	Related Disease	Score	Top Affiliating Genes
1	dengue shock syndrome	31.9	SULT1A3 SENP8 IVNS1ABP IL10 CLEC5A CD209
2	dengue hemorrhagic fever	31.7	SENP8 PTPN11 IVNS1ABP IL10 CLEC5A CD40LG
3	myelitis	31.0	IL10 IFNB1 CCR6
4	neuritis	30.9	IL10 CCL5 CCL4 CCL3
5	neutropenia	30.8	PTPN11 IL10 FCGR1A CD40LG
6	invasive aspergillosis	30.8	IL10 CD209 CCR6
7	kawasaki disease	30.8	FCGR1A CD40LG CCL5
8	plasmodium falciparum malaria	30.8	IL10 CCL5 CCL4 CCL3
9	covid-19	30.7	IL10 IFNB1 CCR6 CCL3
10	severe acute respiratory syndrome	30.7	IL7 IL10 IFNB1 CD209 CCL5 CCL3
11	crimean-congo hemorrhagic fever	30.7	PIK3C2A IL10 IFNB1
12	rubella	30.7	IL10 IFNB1 CD40LG
13	polyradiculoneuropathy	30.7	IL10 CCL5 CCL4
14	murray valley encephalitis	30.7	SENP8 CD209
15	hepatitis e	30.7	IL10 IFNB1 CD40LG
16	proteasome-associated autoinflammatory syndrome 1	30.6	IL10 CCL5 CCL3
17	respiratory syncytial virus infectious disease	30.6	IFNB1 CCL5 CCL3
18	aspergillosis	30.6	IL10 CD209 CCR6 CCL5 CCL3
19	hemophagocytic lymphohistiocytosis	30.6	IL7 IL10 CCR6 CCL5 CCL3
20	middle east respiratory syndrome	30.6	IFNB1 CCR6 CCL3
21	exanthem	30.5	PIK3C2A IL10 CCR6
22	myocarditis	30.5	PIK3C2A IL10 CD40LG CCL5 CCL3
23	acquired immunodeficiency syndrome	30.5	NEAT1 IL10 CD40LG CCL3
24	meningoencephalitis	30.4	IL10 CD40LG CCR6 CCL5
25	viral encephalitis	30.4	IL10 IFNB1 CCR6 CCL5
26	severe covid-19	30.4	IL7 IL10 IFNB1 CCR6 CCL3
27	bacterial sepsis	30.4	IL10 IFNB1 CCR6
28	endocarditis	30.3	PIK3C2A IL10 CCL4
29	human cytomegalovirus infection	30.3	IL10 IFNB1 CCR6
30	zika fever	30.3	IFNB1 CD209
31	allergic disease	30.3	IL10 CCR6 CCL5 CCL3
32	chickenpox	30.3	IL10 IFNB1 CCR6
33	anemia, autoimmune hemolytic	30.3	IL10 CD40LG CCR6
34	mumps	30.3	IL10 IFNB1 CD40LG
35	primary progressive multiple sclerosis	30.2	IL10 IFNB1 CCR6
36	thrombocytopenia	30.2	PTPN11 PIK3C2A IL7 IL10 IFNB1 FCGR1A
37	severe combined immunodeficiency	30.2	IL7 IL10 IFNB1 CD40LG CCR6
38	schistosomiasis	30.2	IL10 CD40LG CCL5 CCL3
39	lymphadenitis	30.2	IL10 CD209 CCR6
40	bronchiolitis	30.2	IL10 CCL5 CCL4 CCL3
41	toxoplasmosis	30.2	PIK3C2A IL10 CD40LG CCL3
42	meningitis	30.2	IL10 CCL5 CCL4 CCL3
43	respiratory failure	30.2	PIK3C2A IL7 IL10 IFNB1 CCR6 CCL5
44	retinal vasculitis	30.2	IVNS1ABP IFNB1 CCR6 CCL4
45	bacterial pneumonia	30.2	IL10 IFNB1 CCR6 CCL3
46	west nile fever	30.2	RNASEL IFNB1 CD209
47	pfeiffer syndrome	30.2	PTPN11 IL10 CD40LG CCR6
48	pneumonia	30.1	PIK3C2A IL10 CD40LG CCL5 CCL3
49	spinal cord disease	30.1	IL10 IFNB1 CCR6
50	hypertension, essential	30.1	SULT1A3 PIK3C2A MIR30E IL10 CD40LG CCR6

Graphical network of the top 20 diseases related to Dengue Disease:

Sources

Symptoms & Phenotypes for Dengue Disease

Human phenotypes related to Dengue Disease:

⁵⁸ ³⁰ (show all 22)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fever ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001945
2	headache ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002315
3	abdominal pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002027
4	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
5	skin rash ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000988
6	pruritus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000989
7	nausea and vomiting ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002017
8	hypotension ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002615
9	hepatomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002240
10	ascites ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001541
11	thrombocytopenia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001873
12	gastrointestinal hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002239
13	epistaxis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000421
14	gingival bleeding ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000225
15	petechiae ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000967
16	bruising susceptibility ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000978
17	lethargy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001254
18	cerebral hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001342
19	diarrhea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002014
20	leukopenia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001882
21	hypoproteinemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003075
22	cardiorespiratory arrest ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0006543

UMLS symptoms related to Dengue Disease:

fever; pruritus

MGI Mouse Phenotypes related to Dengue Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.93	CCL3 CD209 CD40LG FCGR1A HCFC1 IL10
2	immune system	MP:0005387	9.77	CCL3 CCL5 CCR6 CD209 CD40LG CLEC5A
3	hematopoietic system	MP:0005397	9.44	CCL3 CCL5 CCR6 CD209 CD40LG FCGR1A

Sources

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ketotifen

Approved

Phase 4

34580-14-8, 34580-13-7

3827

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Neurotransmitter Agents

Phase 4

Anti-Allergic Agents

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Histamine H1 Antagonists

Phase 4

Histamine Antagonists

Phase 4

Dermatologic Agents

Phase 4

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Montelukast

Approved

Phase 2, Phase 3

158966-92-8

5281040

Protective Agents

Phase 3

Insect Repellents

Phase 3

Heptavalent Pneumococcal Conjugate Vaccine

Phase 3

Leukotriene Antagonists

Phase 2, Phase 3

Anti-Asthmatic Agents

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Respiratory System Agents

Phase 2, Phase 3

Hydrocortisone succinate

Approved

Phase 2

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 2

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 2

50-23-7

3640 5754

Ribavirin

Approved

Phase 2

36791-04-5

37542

Chloroquine

Approved, Investigational, Vet_approved

Phase 1, Phase 2

54-05-7

2719

Ivermectin

Approved, Investigational, Vet_approved

Phase 2

70288-86-7

9812710 6427057

Framycetin

Approved, Experimental, Vet_approved

Phase 2

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Phenol

Approved, Experimental

Phase 2

108-95-2

996

Streptomycin

Approved, Vet_approved

Phase 2

57-92-1

19649

Metformin

Approved

Phase 1, Phase 2

1115-70-4, 657-24-9

4091

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 2

55-56-1

2713 9552079

Kava

Approved, Investigational, Nutraceutical

Phase 2

9000-38-8

Melatonin

Approved, Nutraceutical, Vet_approved

Phase 2

73-31-4

896

Antimetabolites

Phase 2

Hydrocortisone 17-butyrate 21-propionate

Phase 2

Amebicides

Phase 1, Phase 2

Antiprotozoal Agents

Phase 1, Phase 2

Antimalarials

Phase 1, Phase 2

Chloroquine diphosphate

Phase 1, Phase 2

50-63-5

Vaccines

Phase 2

Anti-Infective Agents

Phase 2

Antiparasitic Agents

Phase 2

Hemostatics

Phase 2

Plasma-lyte 148

Phase 2

Hypoglycemic Agents

Phase 1, Phase 2

Chlorhexidine gluconate

Phase 2

Antirheumatic Agents

Phase 2

Interleukin 1 Receptor Antagonist Protein

Phase 2

Antiviral Agents

Phase 2

Papaya

Approved

Phase 1

Aluminum sulfate

Approved

Phase 1

10043-01-3

Interventional clinical trials:

(show top 50) (show all 228)

#	Name	Status	NCT ID	Phase	Drugs
1	Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)	Unknown status	NCT02673840	Phase 4	Ketotifen;Placebo
2	Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage	Unknown status	NCT04076254	Phase 3	Albumins;Fluid
3	A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection	Unknown status	NCT02045069	Phase 2, Phase 3	2 days Ivermectin;3 days Ivermectin;Placebo
4	The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients	Unknown status	NCT00966628	Phase 3	Hypertonic sodium lactate;Ringer's lactate
5	Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR	Unknown status	NCT00938379	Phase 3	20% deet insect repellent;placebo control
6	An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue	Completed	NCT03771963	Phase 3
7	Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia	Completed	NCT02993757	Phase 3
8	A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue	Completed	NCT04313244	Phase 3
9	Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico	Completed	NCT02979535	Phase 3
10	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue	Completed	NCT03423173	Phase 3
11	Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia	Completed	NCT01134263	Phase 3
12	Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia	Completed	NCT01254422	Phase 3
13	Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America	Completed	NCT01374516	Phase 3
14	Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia	Completed	NCT01373281	Phase 3
15	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue	Completed	NCT03341637	Phase 3
16	A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue	Completed	NCT03525119	Phase 3
17	Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru	Completed	NCT01436396	Phase 3
18	Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico	Completed	NCT01411241	Phase 3
19	A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies)	Completed	NCT03342898	Phase 3	Placebo
20	Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial	Recruiting	NCT04673422	Phase 2, Phase 3	Montelukast;Placebo
21	Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan	Recruiting	NCT02406729	Phase 3
22	A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue	Active, not recruiting	NCT03999996	Phase 3
23	Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old	Active, not recruiting	NCT02747927	Phase 3	Placebo
24	Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases	Active, not recruiting	NCT04343521	Phase 3
25	Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines	Terminated	NCT02992418	Phase 3
26	Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research	Unknown status	NCT01973855	Phase 2	Western Medicine;TCM and Western Medicine
27	The Effect of Chloroquine in the Treatment of Patients With Dengue	Unknown status	NCT00849602	Phase 1, Phase 2	Placebo;Chloroquine
28	Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults	Unknown status	NCT01696422	Phase 2
29	Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever	Completed	NCT01619969	Phase 1, Phase 2	celgosivir;placebo
30	Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines	Completed	NCT02628444	Phase 2
31	Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand	Completed	NCT00842530	Phase 2
32	Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years	Completed	NCT00740155	Phase 2
33	Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine	Completed	NCT00730288	Phase 2
34	A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America	Completed	NCT02302066	Phase 2
35	Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America	Completed	NCT02623725	Phase 2
36	Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru	Completed	NCT00788151	Phase 2
37	Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine	Completed	NCT01943825	Phase 2
38	Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children	Completed	NCT00468858	Phase 2
39	An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults	Completed	NCT03746015	Phase 2
40	A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children	Completed	NCT00384670	Phase 1, Phase 2
41	Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines	Completed	NCT01064141	Phase 2
42	Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam	Completed	NCT00875524	Phase 2
43	Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America	Completed	NCT00993447	Phase 2
44	A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore	Completed	NCT02425098	Phase 2
45	Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore	Completed	NCT00880893	Phase 2
46	Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore	Completed	NCT02824198	Phase 2
47	Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US	Completed	NCT00617344	Phase 2
48	Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.	Completed	NCT01550289	Phase 2
49	A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults	Completed	NCT02193087	Phase 2	TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
50	Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.	Completed	NCT01488890	Phase 2

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Sources

Genetic Tests for Dengue Disease

Sources

Anatomical Context for Dengue Disease

Organs/tissues related to Dengue Disease:

MalaCards : Skin, Bone, Endothelial, Liver, T Cells, Monocytes, Kidney

Sources

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 26354)

#	Title	Authors	PMID	Year
1	Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects. ⁶² ⁴¹	Callahan M...Ramstedt U	35939501	2022
2	Disruption of spatiotemporal clustering in dengue cases by wMel Wolbachia in Yogyakarta, Indonesia. ⁶² ⁴¹	Dufault SM...Anders KL	35701454	2022
3	Use of mobile data collection systems within large-scale epidemiological field trials: findings and lessons-learned from a vector control trial in Iquitos, Peru. ⁴¹	Elson WH...Morrison AC	36243698	2022
4	Cardiac tamponade in a patient with dengue fever and lupus nephritis: a case report. ⁵³ ⁶²	Kumar S...Jean R	20089524	2010
5	Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. ⁵³ ⁶²	Belon CA...Frick DN	20108979	2010
6	Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. ⁵³ ⁶²	Conceicao TM...Da Poian AT	19837110	2010
7	Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. ⁵³ ⁶²	Cheng HJ...Lin YS	19822367	2009
8	Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection. ⁵³ ⁶²	Lin RJ...Lin YL	19923450	2009
9	Early diagnosis of dengue virus infection by detection of dengue viral antigen in peripheral blood mononuclear cell. ⁵³ ⁶²	Chunhakan S...Chuansumrit A	19755928	2009
10	Evaluation of dengue NS1 antigen detection tests with acute sera from patients infected with dengue virus in Venezuela. ⁵³ ⁶²	Ramirez AH...Liprandi F	19733994	2009
11	The relationship of interacting immunological components in dengue pathogenesis. ⁵³ ⁶²	Nielsen DG	19941667	2009
12	Neurologic dengue manifestations associated with intrathecal specific immune response. ⁵³ ⁶²	Puccioni-Sohler M...Peralta JM	19858464	2009
13	Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. ⁵³ ⁶²	Chen MC...Lin YS	19592650	2009
14	Super induction of dengue virus NS1 protein in E. coli. ⁵³ ⁶²	Das D...Suresh MR	19232392	2009
15	Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. ⁵³ ⁶²	Krishna VD...Satchidanandam V	19264772	2009
16	Spatio-temporal tracking and phylodynamics of an urban dengue 3 outbreak in São Paulo, Brazil. ⁵³ ⁶²	Mondini A...Nogueira ML	19478848	2009
17	Hanta virus infection during dengue virus infection outbreak in Indonesia. ⁵³ ⁶²	Suharti C...van der Meer JW	19390126	2009
18	Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. ⁵³ ⁶²	Alen MM...Schols D	19264337	2009
19	Detection of dengue nonstructural 1 (NS1) protein in Vietnamese patients with fever. ⁵³ ⁶²	Phuong HL...de Vries PJ	19232866	2009
20	Patterns of dengue virus IgM and IgG antibodies in suspected cases of dengue in Jamaica, 2003-2006. ⁵³ ⁶²	Brown MG...Smikle MF	19478396	2009
21	Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000. ⁵³ ⁶²	Chang SF...Shu PY	19122918	2008
22	Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. ⁵³ ⁶²	Lin CF...Lin YS	18679379	2008
23	Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. ⁵³ ⁶²	Bessoff K...Hunsperger E	18685015	2008
24	Skin lesions in hospitalized cases of dengue Fever. ⁵³ ⁶²	Saleem K...Shaikh I	18940116	2008
25	DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. ⁵³ ⁶²	Wang SF...Chen YM	18593570	2008
26	Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. ⁵³ ⁶²	Gao G...Wilson JM	18788905	2008
27	Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. ⁵³ ⁶²	Dussart P...Baril L	18714359	2008
28	Identification of human hnRNP C1/C2 as a dengue virus NS1-interacting protein. ⁵³ ⁶²	Noisakran S...Yenchitsomanus PT	18471994	2008
29	Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. ⁵³ ⁶²	Bozza FA...Kubelka CF	18578883	2008
30	Use of a commercial enzyme immunoassay to monitor dengue virus replication in cultured cells. ⁵³ ⁶²	Ludert JE...del Angel RM	18439289	2008
31	Treatment of yellow fever. ⁵³ ⁶²	Monath TP	18061688	2008
32	Characterization of Asn130-to-Ala mutant of dengue type 1 virus NS1 protein. ⁵³ ⁶²	Tajima S...Kurane I	18288598	2008
33	CD209 genetic polymorphism and tuberculosis disease. ⁵³ ⁶²	Vannberg FO...Hill AV	18167547	2008
34	Evaluation of the Panbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. ⁵³ ⁶²	Blacksell SD...Day NP	17889487	2008
35	Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. ⁵³ ⁶²	Lazaro-Olan L...Cedillo-Barron L	18279077	2008
36	Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. ⁵³ ⁶²	Avirutnan P...Diamond MS	18052531	2007
37	Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. ⁵³ ⁶²	Sun DS...Chang HH	17958746	2007
38	Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos. ⁵³ ⁶²	Blacksell SD...Newton PN	17715330	2007
39	Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. ⁵³ ⁶²	Hapugoda MD...Khanna N	17898184	2007
40	[Aminotransferases serum levels in patients with Dengue type 3]. ⁵³ ⁶²	Valero C N...Maldonado E M	18180838	2007
41	Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES. ⁵³ ⁶²	Lee YR...Liu HS	17416433	2007
42	Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. ⁵³ ⁶²	Vazquez S...Guzman MG	16914345	2007
43	Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. ⁵³ ⁶²	Falconar AK	17329445	2007
44	Characterization of dengue virus serotype 1 in epidemics in Porto Velho, Rondônia, in 2001-2003. ⁵³ ⁶²	Vieira DS...Batista WC	17653458	2007
45	The distribution of DEN infected people in Dushan and Xingyi area of Yunnan-Guizhou Plateau, China. ⁵³ ⁶²	Liu W...Zhou Y	17257502	2006
46	CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. ⁵³ ⁶²	Sun P...Burgess T	17056582	2006
47	Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. ⁵³ ⁶²	Butthep P...Chuansumrit A	17006283	2006
48	Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). ⁵³ ⁶²	Rodrigo WW...Schlesinger JJ	17005690	2006
49	Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. ⁵³ ⁶²	Naarding MA...Paxton WA	17005819	2006
50	Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. ⁵³ ⁶²	Umareddy I...Vasudevan SG	16894199	2006

Sources

Genes for Dengue Disease

Genes related to Dengue Disease (0 elite genes):

(show all 36)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	153.16	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29031635
2	CD209	CD209 Molecule	Protein Coding	22.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12682107 19941667 16417930 (more) 19264337 16239964 15855154 18593570 16274635 17005819 18167547 16469696
3	IL10	Interleukin 10	Protein Coding	13.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	CD40LG	CD40 Ligand	Protein Coding	12.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9431954 19478396 19858464 (more) 10973453 14607869 16914345 11063489 10391862 15525913 12853395 17715330 1297178 12626461 15956408 9242317 9646004 12873179 15184425 16385170 17898184 10348250 18940116 10973469 10572311 9749624 20089524 19755928 17257502 9606000 11724841 9817913 10473522 17889487 15498040 17056582 9455871 9574674 16210489 9650956
5	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	11.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11022000 17416433 15122797 (more) 16103156 19837110
6	IVNS1ABP	Influenza Virus NS1A Binding Protein	Protein Coding	10.26	Novoseek inferred ⁵³	10698995 11825945 12853395 (more) 18471994 9158059 15184425 18279077 16140430 15780810 18439289 16891505 19122918 19733994 19264772 16894199 18685015 19232392 16103191 18288598 18714359 17958746 11596093 19478848 17653458
7	HCFC1	Host Cell Factor C1	Protein Coding	9.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9649218 11335136
8	SENP8	SUMO Peptidase Family Member, NEDD8 Specific	Protein Coding	9.29	DISEASES inferred ¹⁴
9	IFNB1	Interferon Beta 1	Protein Coding	9.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1571018 19837110 14612562 (more) 15106828
10	CCL4	C-C Motif Chemokine Ligand 4	Protein Coding	8.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18578883 16103156
11	PIK3C2A	Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha	Protein Coding	8.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8274073 10191585
12	FCGR1A	Fc Gamma Receptor Ia	Protein Coding	8.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17005690 10405359
13	CCL3	C-C Motif Chemokine Ligand 3	Protein Coding	8.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9714236 16103156
14	SULT1A3	Sulfotransferase Family 1A Member 3	Protein Coding	8.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17006283
15	RNASEL	Ribonuclease L	Protein Coding	7.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19923450
16	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	7.57	Novoseek inferred ⁵³	10928995 12436482 2149144 (more) 1849979 18052531 9191856 12355369 9268170 19232866 19592650 18679379 17319166 9130232 18788905 19822367 17329445 2063952 16122850 16544248
17	IL7	Interleukin 7	Protein Coding	7.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7622198 8860694 18578883
18	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.37	DISEASES inferred ¹⁴ ¹⁴
19	MIR30E	MicroRNA 30e	RNA Gene	7.26	DISEASES inferred ¹⁴ ¹⁴
20	CLEC5A	C-Type Lectin Domain Containing 5A	Protein Coding	7.22	DISEASES inferred ¹⁴
21	LOC117307477	CD209 Promoter Region	Functional Element	7.07	GeneCards inferred via : Publications (show sections)
22	H2AC18	H2A Clustered Histone 18	Protein Coding	7.03	DISEASES inferred ¹⁴ ¹⁴
23	TNF	Tumor Necrosis Factor	Protein Coding	6.95	DISEASES inferred ¹⁴
24	IFNA1	Interferon Alpha 1	Protein Coding	6.9	DISEASES inferred ¹⁴
25	ERVW-1	Endogenous Retrovirus Group W Member 1, Envelope	Protein Coding	6.9	DISEASES inferred ¹⁴
26	CD8A	CD8a Molecule	Protein Coding	6.8	DISEASES inferred ¹⁴
27	IFT81	Intraflagellar Transport 81	Protein Coding	6.76	DISEASES inferred ¹⁴
28	SERPINA3	Serpin Family A Member 3	Protein Coding	6.74	DISEASES inferred ¹⁴ ¹⁴
29	IL6	Interleukin 6	Protein Coding	6.74	DISEASES inferred ¹⁴
30	CD4	CD4 Molecule	Protein Coding	6.71	DISEASES inferred ¹⁴
31	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.58	DISEASES inferred ¹⁴
32	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.56	DISEASES inferred ¹⁴
33	RIGI	RNA Sensor RIG-I	Protein Coding	6.54	DISEASES inferred ¹⁴
34	ALB	Albumin	Protein Coding	6.54	DISEASES inferred ¹⁴
35	IFNAR1	Interferon Alpha And Beta Receptor Subunit 1	Protein Coding	6.46	DISEASES inferred ¹⁴
36	FURIN	Furin, Paired Basic Amino Acid Cleaving Enzyme	Protein Coding	6.46	DISEASES inferred ¹⁴

Sources

Variations for Dengue Disease

Sources

Expression for Dengue Disease

Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: ³⁵ (show top 50) (show all 93)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	IFI27	interferon alpha inducible protein 27	Blood	+	4.85	0.000
2	RRM2	ribonucleotide reductase regulatory subunit M2	Blood	+	4.48	0.000
3	CEP55	centrosomal protein 55	Blood	+	4.33	0.000
4	BIRC5	baculoviral IAP repeat containing 5	Blood	+	4.30	0.000
5	XIST	X inactive specific transcript	Blood	-	4.25	0.009
6	CD38	CD38 molecule	Blood	+	4.23	0.000
7	DLGAP5	DLG associated protein 5	Blood	+	4.10	0.000
8	BUB1	BUB1 mitotic checkpoint serine/threonine kinase	Blood	+	4.08	0.000
9	IGHM	immunoglobulin heavy constant mu	Blood	+	4.04	0.000
10	MCM10	minichromosome maintenance 10 replication initiation factor	Blood	+	3.99	0.000
11	SHCBP1	SHC binding and spindle associated 1	Blood	+	3.97	0.000
12	PBK	PDZ binding kinase	Blood	+	3.97	0.000
13	TYMS	thymidylate synthetase	Blood	+	3.96	0.000
14	PI3	peptidase inhibitor 3	Blood	-	3.93	0.000
15	CDCA2	cell division cycle associated 2	Blood	+	3.91	0.000
16	SESN3	sestrin 3	Blood	-	3.90	0.000
17	HMMR	hyaluronan mediated motility receptor	Blood	+	3.83	0.000
18	MKI67	marker of proliferation Ki-67	Blood	+	3.83	0.000
19	ZWINT	ZW10 interacting kinetochore protein	Blood	+	3.83	0.000
20	DTL	denticleless E3 ubiquitin protein ligase homolog	Blood	+	3.80	0.000
21	CDK1	cyclin dependent kinase 1	Blood	+	3.78	0.000
22	NCAPG	non-SMC condensin I complex subunit G	Blood	+	3.76	0.000
23	CDT1	chromatin licensing and DNA replication factor 1	Blood	+	3.76	0.000
24	SPC25	SPC25 component of NDC80 kinetochore complex	Blood	+	3.75	0.000
25	CDC20	cell division cycle 20	Blood	+	3.73	0.000
26	CNTNAP3	contactin associated protein family member 3	Blood	-	3.72	0.000
27	TOP2A	DNA topoisomerase II alpha	Blood	+	3.71	0.000
28	CCN3	cellular communication network factor 3	Blood	-	3.71	0.000
29	EIF1AY	eukaryotic translation initiation factor 1A Y-linked	Blood	+	3.69	0.015
30	CCNB2	cyclin B2	Blood	+	3.62	0.000
31	CDKN3	cyclin dependent kinase inhibitor 3	Blood	+	3.62	0.000
32	PCLAF	PCNA clamp associated factor	Blood	+	3.61	0.000
33	KIF2C	kinesin family member 2C	Blood	+	3.60	0.000
34	TK1	thymidine kinase 1	Blood	+	3.59	0.000
35	RPS4Y1	ribosomal protein S4 Y-linked 1	Blood	+	3.57	0.017
36	TTK	TTK protein kinase	Blood	+	3.56	0.000
37	CDC6	cell division cycle 6	Blood	+	3.56	0.000
38	CAV1	caveolin 1	Blood	+	3.56	0.000
39	CENPA	centromere protein A	Blood	+	3.54	0.000
40	CYAT1	immunoglobulin lambda light chain-like	Blood	+	3.52	0.000
41	ASPM	assembly factor for spindle microtubules	Blood	+	3.52	0.000
42	OR2W3	olfactory receptor family 2 subfamily W member 3	Blood	-	3.51	0.000
43	UHRF1	ubiquitin like with PHD and ring finger domains 1	Blood	+	3.50	0.000
44	SELENBP1	selenium binding protein 1	Blood	-	3.50	0.000
45	GINS2	GINS complex subunit 2	Blood	+	3.49	0.000
46	MELK	maternal embryonic leucine zipper kinase	Blood	+	3.47	0.000
47	BUB1B	BUB1 mitotic checkpoint serine/threonine kinase B	Blood	+	3.47	0.000
48	CHEK1	checkpoint kinase 1	Blood	+	3.46	0.000
49	CCNB1	cyclin B1	Blood	+	3.45	0.000
50	KIF11	kinesin family member 11	Blood	+	3.42	0.000

Search GEO for disease gene expression data for Dengue Disease.

Sources

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.62	CCL3 CCL4 CCL5 CCR6 CD209 CD40LG
2	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.5	IL7 IL10 IFNB1 CD40LG CCR6 CCL5
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.28	CCL3 CCL4 CCL5 CCR6 CD40LG IL10
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.04	PTPN11 IL7 IL10 CD40LG CCR6 CCL5
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	12.73	RNASEL PTPN11 IL7 IL10 IFNB1 FCGR1A
6	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.7	IFNB1 CD209 CCL5 CCL4 CCL3
7	NF-kappaB Signaling ³	12.44	RNASEL IL10 CD40LG CCL5
8	Interferon gamma signaling ⁶⁶ Show member pathways Interferon Signaling ⁶⁶ Regulation of IFNG signaling ⁶⁶	12.4	RNASEL PTPN11 IFNB1 FCGR1A
9	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	11.88	CCL3 CCL4 CCL5 CCR6
10	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.87	IL7 IL10 CD209
11	Senescence and autophagy in cancer ⁷⁴	11.8	RNASEL IFNB1 CCL3
12	CCL18 signaling pathway ⁷⁴	11.76	IL10 CCR6 CCL3
13	Microglia pathogen phagocytosis pathway ⁷⁴ Show member pathways GPVI-mediated activation cascade ⁶⁶	11.62	PTPN11 PIK3C2A FCGR1A
14	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.6	IL10 IFNB1 CD209
15	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.57	NEAT1 IL10 CD40LG
16	Innate Lymphoid Cells Differentiation ⁶⁵	11.53	IL7 IL10 CCR6 CCL3
17	Lung fibrosis ⁷⁴	11.51	CCL5 CCL4 CCL3
18	miRNAs involvement in the immune response in sepsis ⁷⁴	11.49	IL10 CCL4 CCL3
19	IL 10 signaling pathway ⁶⁷	11.48	PIK3C2A IL10 CD40LG
20	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.23	IL10 CCL4 CCL3
21	Interleukin-10 signaling ⁶⁶	11.13	IL10 CCL5 CCL4 CCL3
22	Cytokines and inflammatory response ⁷⁴	11.07	IL7 IL10 IFNB1
23	Interactions of natural killer cells in pancreatic cancer ⁷⁴	11.01	CCL5 CCL4 CCL3
24	G-protein signaling_Rap2B regulation pathway ²²	10.84	IL7 IL10 CD40LG CCL5 CCL4 CCL3
25	Pathways of nucleic acid metabolism and innate immune sensing ⁷⁴	10.82	RNASEL IFNB1
26	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	10.73	IL10 IFNB1 CCL5 CCL4 CCL3

Sources

GO Terms for Dengue Disease

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.37	CCL3 CCL4 CCL5 CCR6 CD40LG CLEC5A
2	chemotaxis	GO:0006935	10.08	CCR6 CCL5 CCL4 CCL3
3	response to virus	GO:0009615	10.08	IVNS1ABP IFNB1 CCL5 CCL4
4	monocyte chemotaxis	GO:0002548	10	CCL5 CCL4 CCL3
5	negative regulation of viral genome replication	GO:0045071	9.99	RNASEL IFNB1 CCL5
6	chemokine-mediated signaling pathway	GO:0070098	9.97	CCR6 CCL5 CCL4 CCL3
7	lymphocyte chemotaxis	GO:0048247	9.93	CCL5 CCL4 CCL3
8	leukocyte cell-cell adhesion	GO:0007159	9.91	CCL5 CD209 CD40LG
9	positive regulation of calcium ion transport	GO:0051928	9.88	CCL5 CCL4 CCL3
10	eosinophil chemotaxis	GO:0048245	9.8	CCL5 CCL4 CCL3
11	B cell proliferation	GO:0042100	9.76	IL7 IL10 IFNB1 CD40LG
12	negative regulation by host of viral transcription	GO:0043922	9.73	CCL3 CCL4 CCL5
13	immune response	GO:0006955	9.7	IL7 IL10 FCGR1A CD40LG CCR6 CCL5
14	positive regulation of natural killer cell chemotaxis	GO:2000503	9.1	CCL5 CCL4 CCL3

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chemokine activity	GO:0008009	9.8	CCL5 CCL4 CCL3
2	CCR chemokine receptor binding	GO:0048020	9.73	CCL5 CCL4 CCL3
3	CCR5 chemokine receptor binding	GO:0031730	9.63	CCL5 CCL4 CCL3
4	CCR1 chemokine receptor binding	GO:0031726	9.43	CCL5 CCL4 CCL3
5	cytokine activity	GO:0005125	9.4	IL7 IL10 IFNB1 CD40LG CCL5 CCL4